Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Current and former smokers had better clinical outcomes with immunotherapy following lung cancer than nonsmokers.
This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.
Introducing errors in short-lived RNA causes tumors to present antigens on their cell surface, stimulating an immune response.
Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.
Tecentriq after surgery and chemotherapy delayed recurrence in people with Stage II or III non-small-cell lung cancer.
In a lab study, brief disruptions of gene machinery make tumor cells more “visible” to immune system.
A combination of two immunotherapy drugs may be more effective than the current standard treatment, chemotherapy.
People diagnosed with advanced melanoma may soon have a new treatment option that combines two immunotherapy drugs.
More people treated with Opdivo plus Yervoy reached the 6.5-year survival mark than those treated with either drug alone.
Michael Whitley, 43, has a can-do attitude that helps him navigate a complex path through metastatic kidney cancer.
Alexandra-Chloé Villani, PhD, and her team tackle a perplexing issue—the adverse side effects of immunotherapy drugs.
In patients at high risk of relapse, adjuvant therapy with Keytruda prolonged disease-free survival.
Checkpoint inhibitor doubled disease-free survival time after surgery.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.